EUVIMEDOpdag EUVIMED
Open access · CC BY-NC 4.0

Drug‐induced liver injury from selective androgen receptor modulators, anabolic‐androgenic steroids and bodybuilding supplements in Australia

Emily Nash, Amanda Nicoll iD, Nicholas Batt, Jacob George iD, Varan Perananthan iD, David Prince, Michael Wallace iD, Paul Gow, Karl Vaz, Shivakumar Chitturi, Joan Ericka Flores, Alicia Braund and 7 more

Alimentary Pharmacology & Therapeutics · 2024-04 · 59 (8) · 953-961

DOI: 10.1111/apt.17906 ↗

At a glance

Journal article in Alimentary Pharmacology & Therapeutics, published online on 2024-02-19. Written by Emily Nash and 18 co-authors. Institution: AW Morrow Gastroenterology and Liver Centre, Royal Prince Alfred Hospital, Sydney, New South Wales, Australia. Major MEDLINE topics: Receptors, Androgen, Chemical and Drug Induced Liver Injury. Cited 11 times so far (Crossref); 27 references. The full text is freely available (open access, CC BY-NC 4.0).

AbstractSubjectsBibliografiske oplysningerCiteRelated studies

Abstract (original language)

Background

Reports of DILI due to herbal and dietary supplements have been increasing over time.

Aims

To characterise clinical, laboratory and histopathological phenotypes and outcomes of drug‐induced liver injury (DILI) due to anabolic‐androgenic steroids (AAS), selective androgen receptor modulators (SARMs), and bodybuilding supplements (BBS) in Australia.

Methods

Retrospective case series. Patients presented to nine Australian tertiary hospitals, 2017–2023. DILI was defined biochemically and patients were included if their treating physician attributed DILI to preceding use of AAS, SARMs or BBS. Primary endpoint was time to normalisation of liver biochemistry. Secondary endpoints were hospitalisation for investigation or management of DILI, death attributable to liver injury, and liver transplantation.

Results

Twenty‐three cases of DILI were identified, involving 40 drugs: 18 AAS, 14 SARMs and eight BBS. Patients were predominantly male (22/23), with median age 30 years (IQR 26–42). Most were symptomatic (21/23). Median latency of onset was 58 days (IQR 28–112 days) from drug commencement. Most patients (17/23) were admitted to hospital. Based on updated Roussel Uclaf Causality Assessment Method, DILI was possible in 17/23, probable in 2/23 and unlikely in 4/23. Median time to normalisation of liver biochemistry was 175 days (IQR 70–292 days) from presentation. Three (3/23) were treated with corticosteroids, 14/23 were treated for itch, and one (1/23) underwent liver transplantation. There were no deaths.

Conclusions

The prognosis of DILI from AAS, SARMs and BBS is good although liver transplantation may rarely be required. A detailed drug history is important in uncovering DILI due to these supplements.

Subjects

MeSH terms (MEDLINE)

Receptors, AndrogenChemical and Drug Induced Liver InjuryHumansMaleAdultFemaleAnabolic Androgenic SteroidsRetrospective StudiesAustraliaDietary SupplementsSteroids

Substances

Receptors, AndrogenAnabolic Androgenic SteroidsSteroids

Authors and institutions

  • AW Morrow Gastroenterology and Liver Centre, Royal Prince Alfred Hospital, Sydney, New South Wales, Australia.
  • Sydney Medical School, University of Sydney, Sydney, New South Wales, Australia.
  • Eastern Health, Melbourne, Victoria, Australia.
  • Storr Liver Centre, Westmead Millennium Institute, Westmead Hospital, Westmead, New South Wales, Australia.
  • University of Sydney, Sydney, New South Wales, Australia.
  • Department of Gastroenterology and Hepatology, Westmead Hospital, Westmead, New South Wales, Australia.

ORCID profiles: Amanda Nicoll, Jacob George, Varan Perananthan, Michael Wallace, Ken Liu, Simone I Strasser

Cite

APA

Nash, E., Nicoll, A., Batt, N., George, J., Perananthan, V., Prince, D., Wallace, M., Gow, P., Vaz, K., Chitturi, S., Flores, J. E., Braund, A., Bonnichsen, M., Riordan, S., Humphris, J., Duong, T., McKenzie, C., Liu, K., & Strasser, S. I. (2024). Drug‐induced liver injury from selective androgen receptor modulators, anabolic‐androgenic steroids and bodybuilding supplements in Australia. Alimentary Pharmacology & Therapeutics, 59(8), 953-961. https://doi.org/10.1111/apt.17906

Vancouver

Nash E, Nicoll A, Batt N, George J, Perananthan V, Prince D, et al. Drug‐induced liver injury from selective androgen receptor modulators, anabolic‐androgenic steroids and bodybuilding supplements in Australia. Alimentary Pharmacology & Therapeutics. 2024;59(8):953-961. doi:10.1111/apt.17906

BibTeX
@article{Nash2024,
  author = {Nash, Emily and Nicoll, Amanda and Batt, Nicholas and George, Jacob and Perananthan, Varan and Prince, David and Wallace, Michael and Gow, Paul and Vaz, Karl and Chitturi, Shivakumar and Flores, Joan Ericka and Braund, Alicia and Bonnichsen, Mark and Riordan, Stephen and Humphris, Jeremy and Duong, Tuan and McKenzie, Catriona and Liu, Ken and Strasser, Simone I},
  title = {Drug‐induced liver injury from selective androgen receptor modulators, anabolic‐androgenic steroids and bodybuilding supplements in Australia},
  journal = {Alimentary Pharmacology & Therapeutics},
  year = {2024},
  volume = {59},
  number = {8},
  pages = {953--961},
  doi = {10.1111/apt.17906}
}
Start for free →